AstraZeneca Boosts Rare Disease Pipeline With Ionis Antisense Candidate

Pays $200m Upfront

 
• By Ayisha Sharma
AstraZeneca And Ionis Have A Track Record of Dealmaking Together • Source: Alamy

More from Rare Diseases

More from Scrip